Pfizer's Financial Performance in Q1 2025

Pfizer Inc. disclosed its first-quarter financial results for the fiscal year 2025, revealing an 8% decrease in revenue, totaling $13.7 billion. The company also experienced a 5% drop in net income, which settled at $2.97 billion, alongside a similar 5% decline in diluted earnings per share (EPS) to $0.52.

Leadership's Perspective on Financial Health

David Denton, Pfizer's Chief Financial Officer, commented on the results, stating, "Our commitment to operational efficiency and financial discipline is yielding robust outcomes for our bottom line. We are currently on track to meet the upper range of our 2025 Adjusted diluted EPS guidance."

Market Reaction to the Announcement

Following the release of the financial report, Pfizer's stock saw a modest increase of 0.65% in premarket trading, indicating a positive investor response to the company's current trajectory.